Bristol Myers Squibb (BMY) Receivables (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Receivables data on file, last reported at $9.5 billion in Q1 2026.

• Receivables for Q1 2026 came in at $9.5 billion, down 14.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.5 billion (down 14.45% YoY), and the FY2025 annual result was $11.6 billion, up 4.26% from the prior year.
• Receivables retreated to $9.5 billion in Q1 2026 per BMY's latest filing, from $11.6 billion in the prior quarter.
• Over five years, Receivables peaked at $13.2 billion in Q3 2025 and troughed at $8.9 billion in Q1 2022.
• A 5-year average of $11.2 billion and a median of $11.1 billion in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2024 and 2026: Receivables gained 24.56% in 2024, then decreased 14.45% in 2026.
• A 5-year view of Receivables shows it stood at $10.4 billion in 2022, then advanced by 9.11% to $11.3 billion in 2023, then retreated by 1.81% to $11.1 billion in 2024, then rose by 4.26% to $11.6 billion in 2025, then decreased by 18.0% to $9.5 billion in 2026.
• Business Quant data shows BMY's Receivables at $9.5 billion in Q1 2026, $11.6 billion in Q4 2025, and $13.2 billion in Q3 2025.